Table 1. Relevant parameters of all groups.
| CON | PD | PD-MCI | PDD | |
|---|---|---|---|---|
| N | 36 | 22 | 15 | 29 |
| Gender m/f | 19/17 | 16/6 | 8/7 | 17/12 |
| Agea | 60 ± 12 | 69 ± 8 | 65 ± 9 | 74 ± 8 |
| Tau (pg/ml) | 327 ± 185 | 256 ± 82 | 285 ± 109 | 317 ± 198 |
| Aß 1–42 (pg/ml) | 841 ± 295 | 682 ± 400 | 977 ± 315 | 774 ± 262 |
| CSF alpha- synuclein (pg/ml) | 1401 ± 689 | 1037 ± 381 | 1361 ± 487 | 1306 ± 512 |
| Serum alpha-synuclein (ng/ml) | 29.7 ± 32.9 | 19.4 ± 21.7 | 32.6 ± 46.3 | 17.1 ± 33.9 |
| MMSEb | N/A | 29 ± 2 | 28 ± 2 | 22 ± 5 |
Tau and Aβ 42 was measured in CSF. Data are indicated as mean ± SD. CON, control; PD, Parkinson’s disease; PDD, Parkinson’s disease with dementia; aSignificant difference between PDD and control as well as PDD and PD-MCI patients (p < 0.05); bSignificant difference between PDD and PD as well as PDD and PD-MCI patients (p < 0.01).